These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. The other side of clinical trial monitoring; assuring data quality and procedural adherence. Williams GW Clin Trials; 2006; 3(6):530-7. PubMed ID: 17170037 [TBL] [Abstract][Full Text] [Related]
29. American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites. Zon R; Meropol NJ; Catalano RB; Schilsky RL J Clin Oncol; 2008 May; 26(15):2562-7. PubMed ID: 18390967 [TBL] [Abstract][Full Text] [Related]
30. Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration. Khin NA; Chen YF; Yang Y; Yang P; Laughren TP J Clin Psychiatry; 2012 Jun; 73(6):856-64. PubMed ID: 22687813 [TBL] [Abstract][Full Text] [Related]
31. Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis. Dimitroulis IA Respir Care; 2014 Sep; 59(9):1450-5. PubMed ID: 24782550 [TBL] [Abstract][Full Text] [Related]
32. Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials. du Bois RM; Nathan SD; Richeldi L; Schwarz MI; Noble PW Am J Respir Crit Care Med; 2012 Oct; 186(8):712-5. PubMed ID: 22798316 [TBL] [Abstract][Full Text] [Related]
33. The web of clinical trial registration obligations: have foreign clinical trials been caught? Hathaway CR; Manthei JR; Haas JB; Meltzer ED Food Drug Law J; 2009; 64(2):261-75. PubMed ID: 19999283 [TBL] [Abstract][Full Text] [Related]
34. [Globalization of clinical trials]. Akaza H; Fukuoka M; Ohtsu A; Usami M; Ikeda T; Aiba K; Isonishi S; Ohashi Y; Saijo N; Sone S; Tsukagoshi S; Tsuruo T; Kato M; Mikami O; Dong RP; von Euler M; Blackledge G; Stribling D Gan To Kagaku Ryoho; 2003 Apr; 30(4):555-65. PubMed ID: 12722692 [TBL] [Abstract][Full Text] [Related]
35. A methodology for successfully producing global translations of patient reported outcome measures for use in multiple countries. Two R; Verjee-Lorenz A; Clayson D; Dalal M; Grotzinger K; Younossi ZM Value Health; 2010; 13(1):128-31. PubMed ID: 19695006 [TBL] [Abstract][Full Text] [Related]
36. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Kane RC; Farrell AT; Sridhara R; Pazdur R Clin Cancer Res; 2006 May; 12(10):2955-60. PubMed ID: 16707588 [TBL] [Abstract][Full Text] [Related]
37. Detailed review and analysis of complex radiotherapy clinical trial planning data: evaluation and initial experience with the SWAN software system. Ebert MA; Haworth A; Kearvell R; Hooton B; Coleman R; Spry N; Bydder S; Joseph D Radiother Oncol; 2008 Feb; 86(2):200-10. PubMed ID: 18077034 [TBL] [Abstract][Full Text] [Related]
38. Usefulness of a disease severity staging classification system for IPF in Japan: 20 years of experience from empirical evidence to randomized control trial enrollment. Homma S; Sugino K; Sakamoto S Respir Investig; 2015 Jan; 53(1):7-12. PubMed ID: 25542598 [TBL] [Abstract][Full Text] [Related]
39. The big clinical trials in idiopathic pulmonary fibrosis. Luppi F; Spagnolo P; Cerri S; Richeldi L Curr Opin Pulm Med; 2012 Sep; 18(5):428-32. PubMed ID: 22759771 [TBL] [Abstract][Full Text] [Related]